X4 Pharmaceuticals, Inc. Share Price

Equities

XFOR

US98420X1037

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 17:00:38 30/05/2024 BST 5-day change 1st Jan Change
0.938 USD +0.37% Intraday chart for X4 Pharmaceuticals, Inc. +4.39% +12.06%
Sales 2024 * 21.88M 1.72B Sales 2025 * 51.28M 4.02B Capitalization 157M 12.32B
Net income 2024 * -112M -8.79B Net income 2025 * -109M -8.55B EV / Sales 2024 * 7.17 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.06 x
P/E ratio 2024 *
-1.71 x
P/E ratio 2025 *
-2.03 x
Employees 116
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.05%
1 week+4.39%
Current month-16.11%
1 month-16.11%
3 months-6.97%
6 months+20.46%
Current year+12.06%
More quotes
1 week
0.86
Extreme 0.8602
0.98
1 month
0.86
Extreme 0.86
1.20
Current year
0.70
Extreme 0.7004
1.60
1 year
0.57
Extreme 0.5723
2.58
3 years
0.57
Extreme 0.5723
9.70
5 years
0.57
Extreme 0.5723
17.38
10 years
0.57
Extreme 0.5723
23.93
More quotes
Managers TitleAgeSince
Founder 54 30/06/14
Director of Finance/CFO 44 31/08/18
Chief Operating Officer 63 31/12/16
Members of the board TitleAgeSince
Chairman 69 30/06/18
Director/Board Member 69 31/08/17
Founder 54 30/06/14
More insiders
Date Price Change Volume
30/05/24 0.9397 +0.56% 178 971
29/05/24 0.9345 -0.92% 693,598
28/05/24 0.9432 +4.44% 1,080,726
24/05/24 0.9031 +0.33% 1,068,594
23/05/24 0.9001 -0.56% 1,472,004

Delayed Quote Nasdaq, May 30, 2024 at 04:45 pm

More quotes
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.9345 USD
Average target price
4.117 USD
Spread / Average Target
+340.57%
Consensus